0001384101-20-000039.txt : 20200304 0001384101-20-000039.hdr.sgml : 20200304 20200304174907 ACCESSION NUMBER: 0001384101-20-000039 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200303 FILED AS OF DATE: 20200304 DATE AS OF CHANGE: 20200304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kennedy Giulia C CENTRAL INDEX KEY: 0001769333 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36156 FILM NUMBER: 20688584 MAIL ADDRESS: STREET 1: 338 MAIN STREET #26E CITY: SAN FRANCISCO STATE: CA ZIP: 94105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERACYTE, INC. CENTRAL INDEX KEY: 0001384101 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 205455398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 243-6300 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: CALDEROME INC DATE OF NAME CHANGE: 20061219 4 1 wf-form4_158336213084937.xml FORM 4 X0306 4 2020-03-03 0 0001384101 VERACYTE, INC. VCYT 0001769333 Kennedy Giulia C 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific & Med Officer Common Stock 2020-03-03 4 M 0 3750 6.45 A 102872 D Common Stock 2020-03-03 4 M 0 1563 5.43 A 104435 D Common Stock 2020-03-03 4 M 0 5313 9.05 A 109748 D Common Stock 2020-03-03 4 M 0 4407 5.98 A 114155 D Common Stock 2020-03-03 4 S 0 30542 25.3489 D 83613 D Common Stock 2020-03-03 4 S 0 2339 25.9051 D 81274 D Stock Option (right to buy) 6.45 2020-03-03 4 M 0 3750 6.45 D 2026-02-28 Common Stock 3750.0 2 D Stock Option (right to buy) 5.43 2020-03-03 4 M 0 1563 5.43 D 2026-03-14 Common Stock 1563.0 522 D Stock Option (right to buy) 9.05 2020-03-03 4 M 0 5313 9.05 D 2027-03-02 Common Stock 5313.0 21250 D Stock Option (right to buy) 5.98 2020-03-03 4 M 0 4407 5.98 D 2028-03-01 Common Stock 4407.0 35250 D The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Represents weighted average sales price. Sale prices for the transactions range from $24.77 to $25.75. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $25.78 to $26.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. The option is fully vested. The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. /s/ Keith Kennedy as attorney-in-fact 2020-03-04